ORAL CONTRACEPTIVE DOSAGE FORMS AND METHODS OF MAKING SUCH DOSAGE FORMS

• US 20090269403A1
• Filed: 04/23/2009
• Published: 10/29/2009
• Est. Priority Date: 04/24/2008
• Status: Abandoned Application

• Current Assignee: Evestra, Inc.
• Original Assignee: Evestra, Inc.
• Inventors: Hughey, Justin R., Shaked, Ze'ev
• Application Number:
  US12/429,009
• Publication Number:
  US 20090269403A1
• Time in Patent Office: Days
• US Class Current: 424/480
• CPC Class Codes: A61K 31/565 not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
• CPC Class Codes: A61K 9/1635 obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
• CPC Class Codes: A61K 9/1652 Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin homeopathic globules A61K9/1623
• CPC Class Codes: A61K 9/284 obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
• CPC Class Codes: A61K 9/2866 Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
• CPC Class Codes: A61K 9/2886 having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer of the type active core-drug layer-inactive layer A61K9/209
• CPC Class Codes: A61P 15/00 Drugs for genital or sexual disorders for disorders of sex hormones A61P5/24; Contraceptives

Abstract

Disclosed herein are oral dosage forms and methods of their use, in particular oral dosage systems for the delivery of drugs for use as a female oral contraceptive. In an embodiment, an oral dosage form includes a progestogen dispersed in an enteric polymer and an estrogen.

Claims

1. An oral dosage form comprising a progestogen dispersed in an enteric polymer and an estrogen.

4. The oral dosage form of claim 1, wherein the progestogen is drospirenone.

5. The oral dosage form of claim 1, wherein the estrogen is ethinylestradiol.

6. The oral dosage form of claim 1, wherein the estrogen is a nitrated estrogen derivative.

7. The oral dosage form of claim 6, wherein the nitrated estrogen derivative has the structure:

where R₁ is hydrogen, C₁-C₈ alkyl, cycloalkyl, or C₁-C₈ acyl;

R₂ is hydrogen or C₁-C₈ alkyl;

R₃ is hydrogen, hydroxy or C₁-C₈ alkyl;

R₄ is hydrogen or C₁-C₈ alkyl;

where each R₅ and R₆ is, independently, hydrogen or nitrate; and

wherein at least one of R₅ and R₆ is a nitrate group.

10. The oral dosage form of claim 1, wherein the enteric polymer comprises a hydroxypropyl methylcellulose based polymer.

11. The oral dosage form of claim 10, wherein the hydroxypropyl methylcellulose based polymer comprises hydroxypropyl methylcellulose acetate succinate.

13. The oral dosage form of claim 1, further comprising one or more hydroxyalkyl celluloses.

2-3. -3. (canceled)

8-9. -9. (canceled)

12. (canceled)

14-17. -17. (canceled)

18. An oral dosage form comprising a tablet, wherein the tablet comprises:

progestogen particles, wherein the progestogen particles comprise a progestogen dispersed in an enteric polymer; and

an estrogen.

21. The oral dosage form of claim 18, wherein the progestogen is drospirenone.

22. The oral dosage form of claim 18, wherein the estrogen is ethinylestradiol.

23. The oral dosage form of claim 18, wherein the estrogen is a nitrated estrogen derivative.

24. The oral dosage form of claim 23, wherein the nitrated estrogen derivative has the structure:

where R₁ is hydrogen, C₁-C₈ alkyl, cycloalkyl, or C₁-C₈ acyl;

R₂ is hydrogen or C₁-C₈ alkyl;

R₃ is hydrogen, hydroxy or C₁-C₈ alkyl;

R₄ is hydrogen or C₁-C₈ alkyl;

where each R₅ and R₆ is, independently, hydrogen or nitrate; and

wherein at least one of R₅ and R₆ is a nitrate group.

29. The oral dosage form of claim 18, wherein the enteric polymer comprises a hydroxypropyl methylcellulose based polymer.

30. The oral dosage form of claim 29, wherein the hydroxypropyl methylcellulose based polymer comprises hydroxypropyl methylcellulose acetate succinate.

32. The oral dosage form of claim 18, wherein the progestogen particles further comprise one or more hydroxyalkyl celluloses.

35. The oral dosage form of claim 18, wherein the tablet further comprises microcrystalline cellulose.

39. The oral dosage form of claim 18, wherein the oral dosage form further comprises a coating covering at least a portion of the tablet, wherein the coating comprises an enteric polymer.

19-20. -20. (canceled)

25-28. -28. (canceled)

31. (canceled)

33-34. -34. (canceled)

36-38. -38. (canceled)

40-77. -77. (canceled)

78. An oral dosage form comprising a tablet, wherein the tablet comprises:

drospirenone particles, wherein the drospirenone particles comprise drospirenone dispersed in an enteric polymer, wherein the enteric polymer comprises hydroxypropyl methyl cellulose acetate succinate; and

ethinylestradiol;

wherein the tablet is at least partially coated with an enteric polymer.

79. A method of producing a contraceptive state in a subject comprising administering to a subject an oral dosage form comprising an effective amount of a progestogen dispersed in an enteric polymer and an effective amount of an estrogen.

80-172. -172. (canceled)

173. A method of formulating an oral dosage form, comprising:

forming a mixture of an enteric polymer and a progestogen;

heating at least a portion of the enteric polymer to a temperature at or above the glass transition temperature of the enteric polymer to form a heated mixture of enteric polymer and the progestogen;

permitting the heated mixture to solidify as a solid mass comprising the progestogen dispersed in the enteric polymer; and

combining the progestogen dispersed in an enteric polymer with an estrogen to form the oral dosage form.

174-277. -277. (canceled)